Neonatal treatment with luteinizing hormone-releasing hormone analogs alters peripheral lymphocyte subsets and cellular and humorally mediated immune responses in juvenile and adult male monkeys.
We examined the effect of treatment with a LH-releasing hormone (LHRH) agonist (Ag), antagonist (Ant), or Ant and androgen (Ant/And) for the first 4 months of postnatal life on lymphocyte subsets and cellular and humorally mediated immune responses in juvenile and adult male monkeys. We also determined the effect of 9 weeks of Ant treatment on lymphocyte subsets in adult male monkeys. Adult male monkeys that had been treated neonatally with an Ag had increased levels of CD8-positive (CD8+) T-cells and reduced levels of B-cells compared to vehicle-treated controls. Lymphocytes from these animals also showed an elevated proliferative response to a variety of mitogens compared to cells from control animals. Antibody production in response to tetanus toxoid was normal in treated animals. Other neonates treated with Ant/And exhibited subnormal levels of lymphocytes, CD8+ T-cells, and B-cells at 4 months of age. Similar changes, but of lesser magnitude, were observed in animals treated with Ant alone. At 6 months of age, lymphocytes from both groups of Ant-treated monkeys exhibited an above normal proliferative response to streptolysin-O, but not to other mitogens. At 18 months of age, animals treated with Ant alone produced more antitetanus antibody in response to a tetanus toxoid booster than the controls or Ant/And-treated animals. Ant treatment was without major effect on lymphocyte subsets in adult monkeys. Serum LH and testosterone levels declined, and there was a small but significant increase in B-cells, lymphocytes expressing the interleukin-2 receptor, and the CD4+/CD8+ T-cell ratio during treatment, but these parameters normalized during the posttreatment period. The data suggest that chronic neonatal treatment with an Ag or Ant alters the development of immune system responses in male primates. The significance of these changes and their impact on the ability of these animals to respond to pathogenic agents is under investigation.
Mann
D R
DR
Morehouse School of Medicine, Emory University School of Medicine, Atlanta, Georgia 30310.
Ansari
A A
AA
Akinbami
M A
MA
Wallen
K
K
Gould
K G
KG
McClure
H M
HM
D000375:Aging / Q000276:immunology* / Q000502:physiology; D000818:Animals; D000831:Animals, Newborn; D000917:Antibody Formation / Q000276:immunology*; D016175:B-Lymphocyte Subsets / Q000166:cytology / Q000276:immunology / Q000648:ultrastructure; D016516:CD4-CD8 Ratio; D002452:Cell Count; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000494:pharmacology*; D007107:Immune System / Q000187:drug effects / Q000502:physiology; D007111:Immunity, Cellular / Q000276:immunology*; D007986:Luteinizing Hormone / Q000097:blood; D016131:Lymphocyte Subsets / Q000166:cytology* / Q000276:immunology* / Q000502:physiology; D008253:Macaca mulatta / Q000276:immunology*; D008297:Male; D008934:Mitogens / Q000494:pharmacology; D015375:Receptors, Interleukin-2 / Q000032:analysis; D016176:T-Lymphocyte Subsets / Q000166:cytology / Q000276:immunology / Q000648:ultrastructure; D013739:Testosterone / Q000097:blood
D008934:Mitogens; D015375:Receptors, Interleukin-2; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D007986:Luteinizing Hormone